StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Mizuho Reiterates Outperform Rating on Biogen (BIIB)
May 14, 2026 8:17 AM
Mizuho analyst Salim Syed reiterated an Outperform rating and $236.00 price target on Biogen (NASDAQ: BIIB).The analyst comments "This morning ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Next Articles
Wolfe Research on Biogen (BIIB): 'Re-mem-BIIB-er This Day, BIIB Is Moving Tau Forward'
May 14, 2026 7:44 AM
Stifel on Biogen (BIIB): 'We want to be a little cautious here until we see the full data'
May 14, 2026 7:29 AM
Biogen stock jumps 10% on positive phase 2 diranersen data for Alzheimer’s
May 14, 2026 7:16 AM
Biogen's diranersen shows tau reduction in Alzheimer's trial
May 14, 2026 6:59 AM
Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer’s Disease
May 14, 2026 6:59 AM
